Tilray Brands Inc vs Under Armour Inc Class A — how do they compare? Tilray Brands Inc trades at $3.61 (market cap $530.54M), while Under Armour Inc Class A trades at $4.74 (market cap $2.07B). The key difference: Under Armour Inc Class A is far larger — about 3.9× Tilray Brands Inc's market cap, and Under Armour Inc Class A is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tilray Brands Inc for 31 Days and Under Armour Inc Class A for 18 Days on average.
| TLRY | UA | |
|---|---|---|
Market Cap | $530.54M | $2.07B |
Volume | 9,099,075 | 2,680,141 |
Sector | Health | Consumer Cyclical |
52-Week High | $21.00 | $7.88 |
52-Week Low | $3.57 | $3.96 |
Typical Hold Time | 31 Days | 18 Days |
Enterprise Value | $684.46M | $3.05B |
Signals from Pluang's Aura AI — not financial advice
TLRY trades at $3.715, down 1.72% on the day and near its 52-week low, reflecting persistent bearish technical momentum. The company reported revenue of $821.31M in 2025 but a substantial net loss of -$2.19B, with negative cash flow from operations. Recent quarters show consistent earnings misses versus expectations, though analyst consensus suggests a high price target of $65.01 amid mixed sentiment.
The outlook remains challenged by profitability issues and high debt, but potential catalysts include U.S. cannabis regulatory changes. Investment opportunities hinge on speculative regulatory shifts, while risks include ongoing losses, competitive pressures, and reliance on financing activities to sustain operations.
Under Armour (UA) trades at $4.70, down 0.42% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company faces significant fundamental challenges with declining revenue ($5.16B in 2025 to $4.9B in 2026) and negative profitability metrics, including a -9.99% net income margin and -29.82% ROE. Recent earnings show volatility with two beats and one miss in the last four quarters, while cash flow remains negative across all categories.
The outlook remains challenging with declining revenue trends and persistent profitability issues offset by relatively low valuation multiples. Investment opportunity exists if management can stabilize sales and improve margins, but risks include continued consumer demand weakness and competitive pressures in the athletic apparel sector. Analyst sentiment is mixed with 41% buy ratings but growing concerns about the company's turnaround prospects.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →